Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0XLSWN)
| ADC Name |
SC-006
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SC-006
Click to Show/Hide
|
|||||
| Organization |
Stemcentrx (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-RNF43 antibody
|
Antibody Info | ||||
| Antigen Name |
E3 ubiquitin-protein ligase RNF43 (RNF43)
|
Antigen Info | ||||
| Payload Name |
SG3312 (SC-DR003)
|
Payload Info | ||||
| Payload Target |
Human deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Reactive Cysteines
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | stable disease (SD) |
34%
|
|||
| Patients Enrolled |
Eligible participants must have advanced metastatic CRC refractory to ≥2 prior systemic therapies, ECOG 0-1, and adequate organ function. Key exclusions include prior PBD/IND-based drug exposure, autoimmune/immunodeficiency disorders, IBD history, or recent immunosuppressant use within 14 days prior to treatment. Combination therapy excludes patients with immune-mediated pneumonitis or transplant history.
Click to Show/Hide
|
||||
| Administration Dosage |
As of April 2019, 29 patients were enrolled (n=20 in part A and n=9 in part B). All patients experienced at least one treatment-emergent adverse event (TEAE). Two patients (7%) had dose-limiting toxicities of grade 4 thrombocytopenia. All 29 patients discontinued from the study, with study drug being discontinued for 76% of patients due to progressive disease. One death occurred in part A due to gastrointestinal hemorrhage with possible relation to SC-006. Serious TEAEs occurred in 8 patients (28%); these included thrombocytopenia and malignant neoplasm progression in 2 patients (7%) each.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03035279 | Clinical Status | PHASE1 | ||
| Clinical Description | An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer | ||||
| Primary Endpoint |
Safety assessment focuses on dose-limiting toxicities (DLTs) graded per NCI CTCAE v4.03 during the initial 21-day treatment cycle.
|
||||
| Other Endpoint |
Efficacy endpoints include overall survival (OS) and progression-free survival (PFS) over approximately 2 years, along with pharmacokinetic parameters (Tmax, AUC, T1/2, Cmax, Ctrough) of SC-006 evaluated over 1 year. Tumor response is measured via objective response rate (ORR), clinical benefit rate (CBR), and duration of response (DOR) using RECIST v1.1 criteria.
Click to Show/Hide
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | progressive disease (PD) |
62%
|
|||
| Patients Enrolled |
Eligible participants must have advanced metastatic CRC refractory to ≥2 prior systemic therapies, ECOG 0-1, and adequate organ function. Key exclusions include prior PBD/IND-based drug exposure, autoimmune/immunodeficiency disorders, IBD history, or recent immunosuppressant use within 14 days prior to treatment. Combination therapy excludes patients with immune-mediated pneumonitis or transplant history.
Click to Show/Hide
|
||||
| Administration Dosage |
As of April 2019, 29 patients were enrolled (n=20 in part A and n=9 in part B). All patients experienced at least one treatment-emergent adverse event (TEAE). Two patients (7%) had dose-limiting toxicities of grade 4 thrombocytopenia. All 29 patients discontinued from the study, with study drug being discontinued for 76% of patients due to progressive disease. One death occurred in part A due to gastrointestinal hemorrhage with possible relation to SC-006. Serious TEAEs occurred in 8 patients (28%); these included thrombocytopenia and malignant neoplasm progression in 2 patients (7%) each.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03035279 | Clinical Status | PHASE1 | ||
| Clinical Description | An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer | ||||
| Primary Endpoint |
Safety assessment focuses on dose-limiting toxicities (DLTs) graded per NCI CTCAE v4.03 during the initial 21-day treatment cycle.
|
||||
| Other Endpoint |
Efficacy endpoints include overall survival (OS) and progression-free survival (PFS) over approximately 2 years, along with pharmacokinetic parameters (Tmax, AUC, T1/2, Cmax, Ctrough) of SC-006 evaluated over 1 year. Tumor response is measured via objective response rate (ORR), clinical benefit rate (CBR), and duration of response (DOR) using RECIST v1.1 criteria.
Click to Show/Hide
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
0%
|
|||
| Patients Enrolled |
Patients with advanced metastatic or unresectable colorectal cancer.
|
||||
| Administration Dosage |
SC-006-monotherapy, 2 to 12 ug/kg IV every 3 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT03035279 | Clinical Status | Phase 1 | ||
| Clinical Description | An open label phase 1 study of SC-006 as a single agent and in combination with ABBV-181 in subjects with advanced colorectal cancer. | ||||
References